Annual report
3034.TEDINET S100W4MB
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥264.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥161.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥13.5bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥13.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥12.8bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥8.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥7.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥159.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥101.9bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥96.0bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥100.6bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥97.5bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥62.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥41.8bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥19.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥12.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥7.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥137.97 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.55 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,521.14 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,414.43 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,314.69 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,189.7 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,124.31 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 6,254 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 5,856 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,746 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 5,620 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,517 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥9.3bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.3bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.0bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.1bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥7.3bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥6.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.3bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.6bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.5bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥6.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥6.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥123.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥93.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥77.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥67.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥63.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥65.3bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥41.1bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥58.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥46.7bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥40.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥36.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥13.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥13.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥174.02 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.61 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.91 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.45 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥34 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,549.24 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,407.23 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,258.81 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.12 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥987.71 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 38,902,785 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 48 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 56 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 49 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 69
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥86m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥66m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥9.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.5bn |
| BPOreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥108m |
| BPOreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥87m |
| BPOreportable segment | employees | at 2025-03-31 | 794 pure |
| BPOreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥14.9bn |
| BPOreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥13.6bn |
| BPOreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| BPOreportable segment | segment assets | at 2025-03-31 | ¥8.6bn |
| BPOreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Health Insurance Pharmacyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥171.7bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥171.6bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥93m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2025-03-31 | ¥94.8bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| Pharmaceutical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥35.5bn |
| Pharmaceutical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.2bn |
| Pharmaceutical Businessreportable segment | employees | at 2025-03-31 | 330 pure |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥78.7bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥78.7bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2025-03-31 | ¥66.2bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.3bn |
| Pharmacyreportable segment | employees | at 2025-03-31 | 5027 pure |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥41.6bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.8bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥265.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥264.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2025-03-31 | ¥169.6bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥17.0bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥98m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥486m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥486m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥14.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥3.5bn |
| BPOreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥839m |
| BPOreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥77m |
| BPOreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥13.7bn |
| BPOreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥13.3bn |
| BPOreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥397m |
| BPOreportable segment | segment assets | at 2024-03-31 | ¥8.9bn |
| BPOreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Health Insurance Pharmacyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.0bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥165.2bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥165.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥89m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2024-03-31 | ¥91.9bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥10.7bn |
| Pharmaceutical Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥99m |
| Pharmaceutical Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥74m |
| Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2024-03-31 | ¥2.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥412m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥180.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥180.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥486m |
| —segment total | segment assets | at 2024-03-31 | ¥103.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥11.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,633
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 66 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 48 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 2 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 6 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.217 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.944 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.964 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.444 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.501 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.421 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.450 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.534 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 2.168 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.135 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03476-000PharmacyReportableSegmentMember | 5027 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03476-000PharmacyReportableSegmentMember | 1967 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03476-000BPOReportableSegmentsMember | 794 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03476-000BPOReportableSegmentsMember | 300 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 330 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 239 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 103 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 17 | |
| Number of employees | CurrentYearInstant | 6254 | |
| Average number of temporary workers | CurrentYearInstant | 2523 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 48 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 6 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 45.8 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 3.7 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7194000 | JPY |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| All employees calculated based on provisions of act on promotion of womens active engagement in professional life ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.215 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.400 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.722 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.677 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 1.030 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.143 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.667 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.655 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.642 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.913 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.178 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.636 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.785 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |